ArticleScience translational medicine2024
Human OX40L-CAR-T
Abstract read
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Macrophage Trogocytosis of Tumor Cells Drives the Immunosuppression of Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs.Molecular therapy. Advances · 2026Article
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Next-Generation regulatory T cell therapies: Translational considerations for inflammatory bowel disease.Human immunology · 2026Review
- Engineered CD40-biosensor-expressing Treg cells as a cell therapy approach for inflammatory diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- CAR Treg therapies for neurodegenerative diseases.iScience · 2026Review
- Obstacles and improvement strategies for CAR-T cell therapy in solid tumors.Discover oncology · 2026Review
- Regulatory T cell approaches for graft-versus-host disease prevention.Current opinion in immunology · 2026Review
- Emerging Therapeutics in Rheumatoid Arthritis.Current rheumatology reports · 2026Review
- CAR-engineered cell therapies: current understandings and future perspectives.Molecular biomedicine · 2026Review
- Immune modulation for β-cell replacement in type 1 diabetes.Frontiers in immunology · 2026Review
- Regulatory T cells in the era of cell and gene therapy: biology, clinical translation, and future prospects.Frontiers in immunology · 2026Review
- Beyond Foxp3 and TSDR: a dual epigenetic lock framework for treg stability and plasticity.Frontiers in immunology · 2026Review
- Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.Journal of hematology & oncology · 2025Review
- Chronic Graft-versus-host Disease, Part 1: How Preclinical Models Shape Our Understanding of Biology and Pave the Way for Future Therapeutic Interventions.Transplantation · 2025Review
- Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025Review
- Effects of CRISPR-Cas9-mediatedMolecular therapy. Methods & clinical development · 2025Article
- Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A multi-omics resource of B cell activation reveals genetic mechanisms for immune-mediated diseases.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Xianliang RuiDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0009-0007-1219-4382
Francesca Alvarez CalderonDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-5620-8431
Holly WobmaHarvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-8978-3184
Ulrike GerdemannDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-3600-0366
Alexandre AlbaneseDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-7093-574X
Lorenzo CagninDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Connor McGuckinDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-8860-9926
Katherine A MichaelisDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Kisa NaqviDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-8161-3885
Bruce R BlazarDivision of Pediatric Blood and Marrow Transplant and Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-9608-9841
Victor TkachevDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-6011-0576
Leslie S KeanDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-0475-3926
Funding
Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI LARSEN, CHRISTIAN P. · 2002 to 2022
$54.1MTrial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MProject 2: The New Era of Cellular Therapies For Lung Transplant ToleranceU19AI174967 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Joren C Madsen · 2023 to 2026
$18.8MSingle Cell Analysis and ImmunogeneticsP01HL158505 · NHLBI · DANA-FARBER CANCER INST · PI Kenneth James Livak · 2022 to 2026
$15.3MNovel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3MMOLECULAR BASIS OF ALLERGIC AND IMMUNOLOGIC DISEASET32AI007512 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI Janet Chou, Peter A Nigrovic · 1996 to 2026
$13.1MProject 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft ToleranceP01HL158504 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 2021 to 2025
$12.1MResearch Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MIn Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4MNongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1MPOSTGRADUATE TRAINING IN PEDIATRIC ONCOLOGYT32CA082086 · NCI · UNIVERSITY OF COLORADO DENVER · PI GORE, LIA · 2000 to 2015
$4.1MNCI NIH HHS P01 CA065493NCI NIH HHS T32 CA082086NCI NIH HHS T32 CA136432NHLBI NIH HHS P01 HL158504NHLBI NIH HHS P01 HL158505NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL147324NHLBI NIH HHS R01 HL155114NIAID NIH HHS R37 AI034495NIAID NIH HHS T32 AI007512NIAID NIH HHS U19 AI051731NIAID NIH HHS U19 AI174967
Abstract
Regulatory T cells (T
Indexed as
Antigen-Presenting CellsOX40 LigandT-Lymphocytes, RegulatoryAnimalsCell ProliferationForkhead Transcription FactorsGraft vs Host DiseaseHumansLymphocyte ActivationMiceReceptors, Chimeric AntigenForkhead Transcription FactorsOX40 LigandReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.